A COMPARATIVE STUDY OF INFLAMMATORY MARKERS LEVELS IN PATIENTS OF TUBERCULOSIS AND COVID-TB COINFECTION

APARAJITA KUSHWAHA; SOHIL TAKODARA; NEHA SHARMA; BADRI LAL JAT; RAJU RAM

doi:10.22159/ajpcr.2023v16i8.49075

Authors

APARAJITA KUSHWAHA Department of Biochemistry, RR Dental College, Udaipur, Rajasthan, India
SOHIL TAKODARA Department of Biochemistry, GMCH, Udaipur, Rajasthan, India.
NEHA SHARMA Department of Biochemistry, SABVGMC, Faridabad, Haryana, India
BADRI LAL JAT Department of Biochemistry, CUSMC, Surendranagar, Gujarat, India
RAJU RAM Department of Biochemistry, PMCH, Udaipur, Rajasthan, India

DOI:

https://doi.org/10.22159/ajpcr.2023v16i8.49075

Keywords:

COVID-19, TB, CRP, D-DIMER

Abstract

Objective: The outbreak of COVID-19 has increased the vulnerability of global population to diseases; above all, the patients suffering from tuberculosis (TB) COVID-19. Both being diseases of the respiratory tract, a confection of the two might cause severe implications. The WHO has set a goal of eradicating TB globally by the year 2035 (END-TB program). To achieve this goal, various initiatives are being taken with respect to early diagnosis, screening – research and development of new diagnostic as well as treatment tools. Although, the pandemic largely interrupted these initiatives setting back progress by approximately a decade; it should not be overlooked that COVID-19 has unlocked new doors to research and development in the niche of infectious diseases. This study was aimed at analyzing of inflammatory markers in patients of TB, COVID-19, and COVID-TB confection.

Methods: A total of 164 patients aged between 18 years to 85 years were included in this study. Total patients (164) were, then, divided into three groups on the basis of their disease diagnosis. The patient groups are as follows: 57 COVID-19-positive patients, 53 COVID-TB coinfection-positive patients, and 54 TB-positive patients. Serological analysis data of C-reactive protein (CRP), D-dimer, and SGOT were statistically analyzed using one-way ANOVA.

Results: The results of analysis of variance showed significant results for all three inflammatory markers with p<0.05. The levels of CRP, D-dimer, and SGOT underwent the highest increase among COVID-TB coinfection patient.

Conclusion: Through this study, it can be concluded that the addition of inflammatory markers testing in TB patients and diagnostic protocols may prove to be of significant assistance in diagnosis of TB and also to estimate the severity of infection in patients of active TB. It is also noteworthy that the levels of these markers were found to be highest in patients suffering from a coinfection of both the diseases.

Downloads

Download data is not yet available.

References

Wilder-Smith A. COVID-19 in comparison with other emerging viral diseases: Risk of geographical spread via travel. Trip Dis Travel Med Vaccines 2018;7:3.

Liu QY, Han F, Pan LP, Jia HY, Li Q, Zhang ZD. Inflammation responses in patients with pulmonary tuberculosis in an intensive care unit. Exp Ther Med 2018;15:2719-26.

Raizada N, Sachdeva KS, Sreenivas A, Kulsange S, Gupta RS, Thakur R, et al. Catching the missing million: Experiences in enhancing TB & DR-TB detection by providing upfront Xpert MTB/RIF testing for people living with HIV in India. PLoS One 2015;10:e0116721.

Global Tuberculosis Report 2021. Available from: https://www.who. int/teams/globa;tuberculosis-programme/tb-reports [Last accessed on 2022 Jul 20].

Rajarajeswari K, Vijay A, Shankar G, Saravanan M. Inflammatory markers in pulmonary TB: A severity and prognostic indicator. Chest 2019;156:A390.

World Health Organization. Impact of the COVID-19 pandemic on TB detection and mortality in 2020. Geneva, Switzerland: WHO; 2021. Available from: https://www.theglobalfund.org/en/news/2021-03-24-tb-testing-in- 2020dropped-drastically-due-to-covid-19 [Last accessed on 2021 Mar 31].

Song WM, Zhao JY, Zhang QY, Liu SQ, Zhu XH, An QQ, et al. COVID-19 and tuberculosis confection: An overview of case reports/ case series and meta-analysis. Front Med (Lausanne) 2021;8:657006.

Singh AK, Singh A, Singh R, Misra A. Hydroxychloroquine in patients with COVID-19: A systematic review and meta-analysis. Diabetes Metab Syndr 2020;14:589-96.

Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis 2020;96:467-74.